; (2) request an emergency use authorization of the product, as appropriate, under section 564 of the Federal Food, Drug, and Cosmetic Act (or enter into a contract with another entity to submit an application for such use); or (3) acquire from the holder of an application approved under subsection (c) or (j) of section 505 or section 515 of the Federal Food, Drug, and Cosmetic Act or section 351 of this Act, or cleared under section 510(k) of the Federal Food, Drug, and Cosmetic Act, rights to manufacture such applicable drug. (c) Use (1) In general The Office shall sell a drug produced under this section at a fair price to other entities. Amounts received by the Office from the sale of such drugs shall be used for the activities of the Office. (2) Sale of approved application (A) Availability (i) In general For any applicable drug that the Office is manufacturing, the Office shall, beginning 3 years after the date on which the Office first undertakes manufacturing of such drug and annually thereafter, make available for sale, to any person who commits to manufacturing and marketing the applicable drug, the approved application for the drug. (ii) Continued compliance with FDA requirements The Office shall ensure that any application purchased under clause (i) is consistent with existing standards applied by the Food and Drug Administration related to the transfer of ownership rights for an approved application, including any additional filing requirements that the purchaser would need to be in compliance with due to material changes in information provided in the approved application. (B) Failure to use If the Office makes a determination that a person purchasing an approved application under subparagraph (A)— (i) fails to market the applicable drug within 6 months of the date of such purchase